

VioQuest Pharmaceuticals, Inc.  
 Form 4  
 June 17, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BECKER MICHAEL D**

2. Issuer Name and Ticker or Trading Symbol  
 VioQuest Pharmaceuticals, Inc.  
 [VQPH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 180 MT. AIRY ROAD, SUITE 102  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 06/13/2008

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 President and CEO

BASKING RIDGE, NJ 07920

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock				(A) or (D) Price	5,000 <sup>(1)</sup>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Amount of Shares
Stock Options <u>(4)</u>	\$ 3 <u>(1)</u>	06/13/2008		D <u>(2)</u>	501,334 <u>(1)</u>	<u>(2)</u> 11/21/2017	Common Stock, \$.001 par value	50
Stock Options <u>(4)</u>	\$ 0.54	06/13/2008		A <u>(2)</u>	501,334	<u>(2)</u> 11/21/2017	Common Stock, \$.001 par value	50
Stock Options <u>(4)</u>	\$ 3 <u>(1)</u>	06/13/2008		D <u>(3)</u>	29,974 <u>(1)</u>	<u>(3)</u> 11/21/2017	Common Stock, \$.001 par value	29
Stock Options <u>(4)</u>	\$ 0.54	06/13/2008		A <u>(3)</u>	29,974	<u>(3)</u> 11/21/2017	Common Stock, \$.001 par value	29
Stock Options <u>(4)</u>	\$ 0.54	06/13/2008		A	20,000	<u>(5)</u> 06/13/2018	Common Stock, \$.001 par value	20

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BECKER MICHAEL D 180 MT. AIRY ROAD, SUITE 102 BASKING RIDGE, NJ 07920	X		President and CEO	

## Signatures

/s/ Michael D.  
Becker 06/16/2008

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

- (1) Adjusted to reflect a 1-for-10 reverse stock split effective on 4/25/08.

This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 11/21/2007 and provided for vesting in four equal annual installments beginning on 11/21/2008.

- (2) This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 11/21/2007 and provided for vesting under certain contingencies. 21,410 shares vest on 11/21/08 and 8,564 vest on 11/21/09.

- (3) Pursuant to Rule 16b-3 (right to buy); issued under the 2003 Stock Option Plan.

- (4) 6,667 shares vest immediately; 6,667 shares vest on 6/13/09 and 6,666 shares vest on 6/13/10.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.